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The International Society for Pharmacoeconomics
and Outcomes Research Randomized Clinical Tri-
als-Cost-Effectiveness Analysis Task Force (hereaf-
ter referred to as the TF) has undertaken the
challenging task of preparing and issuing a good
research practices guidance document pertaining to
cost-effectiveness analysis alongside clinical trials
[1]. Speciﬁcally, the TF members provide guidance
on various aspects of the design, conduct, and
reporting of such studies. Their primary motiva-
tion is to promote improvement in the quality of
both the conduct and reporting of trial-based cost-
effectiveness analyses thereby enhancing the credi-
bility of these studies in the eyes of decision makers.
Notable contributions of the report include the cita-
tion of an extensive literature, guidance on report-
ing methods and results, and a table of 27 core
recommendations agreed by all the TF members.
The report highlights just how far our knowledge,
experience, and methods, particularly analysis, have
developed since the pioneering days of conducting
economic evaluation through the vehicle of rand-
omized controlled trials [2,3].
The report is a welcome publication that ﬁts
nicely with initiatives within Novartis Pharma AG
to continuously update internal economic evalua-
tion guidance, procedures, and standards documen-
tation initiated almost a decade ago [4]. So we will
integrate content from the TF report within our
guidance manuals. It will be considered along with
other guidance and standards issued by academics,
journals, professional associations, and technology
appraisal bodies. I would urge other industry col-
leagues to do likewise.
I also hope that the report will have an impact on
the consumers of clinical and economic evidence, in
particular pricing and reimbursement authorities
and large groups of health-care purchasers, and that
it will, in turn, lead to greater transparency as to
their evidence needs and the standards that they
wish to see. Not all countries have bodies that are
as transparent as the National Institute for Health
and Clinical Excellence (NICE) [5] nor do most
major pharmaceutical markets require incremental
cost per quality-adjusted life-year calculations. So
explicit guidance is required from the consumers of
evidence and at a time when it is needed most: dur-
ing the design stages of randomized controlled trials
or other research programs. Because the primary
goal of producing evidence is to inform decision
makers, it is difﬁcult to see how we can meet their
standards if they are not known [6].
So what about the future? Will the goal of rais-
ing the quality of cost-effectiveness evidence be
achieved? I think the answer is a resounding yes. I
foresee at least two major developments that will
contribute to bringing this about. First, I think more
jurisdictions will move toward formal requirements
for cost-effectiveness evidence and, perhaps more
signiﬁcantly, there will be more widespread trans-
parent statements of evidence needs and the stand-
ards required for their generation. Most challenges
from pricing and reimbursement bodies are directed
at the strength and relevance of the clinical evidence
base, in particular around the choice of study pop-
ulation, duration  of  observation,  and  the  choice
of comparator. We already see the European Med-
icines Evaluation Agency (EMEA) [7] requesting
registration trials against active comparators so in
turn this should contribute to increasing the rele-
vance of many trials for economic evaluation. But
the EMEA not only issues general guidance, it also
issues disease-speciﬁc guidance relating to the trials
it would like to see. So in the future I see the emer-
gence of disease-speciﬁc guidelines for economic
evaluation to supplement the more generic guidance
as provided in the TF report.
I see a second major development that will con-
tribute to raising the standards of the cost-effective-
ness evidence provided to nonregulatory bodies: the
inevitable emergence of opportunities, if not formal
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requirements, to engage with pricing and reim-
bursement decision makers early in the develop-
ment of a product. Engagement is a fundamental
part of the drug approval process where clinical
development plans and the design of individual tri-
als can be discussed and reﬁned through dialogue
with the EMEA and the US Food and Drug Admin-
istration [8]. But there are currently few opportuni-
ties to engage in such a dialogue with bodies like
NICE. Therefore the opportunity to consult with
the Centers for Medicare and Medicaid Services [9]
about the relevance of study designs for coverage
decisions is to be applauded and I expect similar
opportunities to develop in other countries. I believe
that it is through such early consultation with deci-
sion makers, at the disease-speciﬁc project level,
that sponsors will clearly understand their evidence
needs appropriate to the product, the methods for
its generation, and the standards expected. In meet-
ing the standards of evidence required by decision
makers, the devil is in the detail.
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